All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Comparison of the Short term Efficacy and Serum Markers between Lobaplatin/Paclitaxel- and Carboplatin/Paclitaxel-based Adjuvant Chemotherapy in Patients with Ovarian Cancer

Author(s): Zhihui Li, Ying Chen and Shihong Zhang*
Department of Obstetrics and Gynecology, Affiliated Hospital of Beihua University, Jilin 132011, China

Correspondence Address:
Department of Obstetrics and Gynecology, Affiliated Hospital of Beihua University, Jilin 132011, China, E-mail:

To compare short-term therapeutic efficacies and related changes of serum markers from 2 chemotherapeutic regimes using lobaplatin or carboplatin in combination with paclitaxel in ovarian cancer patients after cytoreductive surgery. 60 patients were recruited with confirmed ovarian cancer. Patients were equally and randomly divided into 2 groups receiving paclitaxel with lobaplatin or carboplatin, respectively. Follow-up was made 6 months post-treatment. The therapeutic efficacy, serum levels of cancer antigen 125/mucin 16 and human epididymis protein 4 as well as the quality-of-life were assessed before and after treatment. No significant difference in therapeutic efficacy was observed between the groups. The response rates at 1, 3 and 6 months were 76.7 % (23/30), 66.7 % (20/30) and 46.7 % (14/30) in the lobaplatin group and 73.3 % (22/30), 63.3 % (19/30), 36.7 % (11/30) in the carboplatin group, respectively. At the end of the chemotherapy, serum levels of human epididymis protein 4 and cancer antigen 125 in both groups returned to normal. However, patients in the lobaplatin group had significantly higher Human epididymis protein 4 and cancer antigen 125 levels than those in the carboplatin group when examined at 3 or 6 month after chemotherapy (p<0.05). Moreover, at the end of follow-up, the quality-of-life score-C30 of the lobaplatin group was better than that of the carboplatin group with statistical significance (p<0.05). Both lobaplatin and carboplatin exert sufficient antitumor efficacy to be included in the standard platinum/paclitaxel-based chemotherapy against ovarian cancer. Lobaplatin, on the other hand, has demonstrated higher efficacy to control the progress of the disease yet less toxicity to warrant better patient quality-of-life.

Full-Text | PDF

Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report